Gemini Phase 3

This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study to compare the efficacy and safety of rivaroxaban versus acetylsalicylic acid.

Awarded By

  • Janssen Research & Development

Contributors

Amount

  • $178,530.00

Start/End

  • 2016 - 2017